TENAYA and LUCERNE: 2-Year Results from the Phase 3 nAMD Trials of Faricimab with Treat-and-Extend Dosing in Year 2
Arshad M. Khanani,Aachal Kotecha,Andrew Chang,Shih-Jen Chen,Youxin Chen,Robyn Guymer,Jeffrey S. Heier,Frank G. Holz,Tomohiro Iida,Jane A. Ives,Jennifer I. Lim,Hugh Lin,Stephan Michels,Carlos Quezada Ruiz,Ursula Schmidt-Erfurth,David Silverman,Rishi Singh,Balakumar Swaminathan,Jeffrey R. Willis,Ramin Tadayoni,Ashkan Abbey,Elmira Abdulaeva,Prema Abraham,Alfredo Adan Civera,Hansjurgen Agostini,Arturo Alezzandrini,Virgil Alfaro,Arghavan Almony,Lebriz Altay,Payam Amini,Andrew Antoszyk,Etelka Aradi,Luis Arias,Jennifer Arnold,Riaz Asaria,Sergei Astakhov,Yury Astakhov,Carl C. Awh,Chandra Balaratnasingam,Sanjiv Banerjee,Caroline Baumal,Matthias Becker,Rubens Belfort,Galina Bratko,William Jr.Z. Bridges,Jamin Brown,David M. Brown,Maria Budzinskaya,Sylvia Buffet,Stuart Burgess,Iksoo Byon,Carlo Cagini,Jorge Calzada,Stone Cameron,Peter Campochiaro,John Carlson,Angela Carneiro,Clement Chan,Emmanuel Chang,Andrew Chang,Daniel Chao,Nauman Chaudhry,Caroline Chee,Andrew Cheek,Shih-Jen Chen,San-Ni Chen,Gemmy Cheung,Saradha Chexal,Mark Chittum,David Chow,Abosede Cole,Brian Connolly,Pierre Loic Cornut,Stephen Couvillion,Carl Danzig,Vesselin Daskalov,Amr Dessouki,Francois Devin,Michael Dollin,Rosa Dolz,Louise Downey,Richard Dreyer,Pravin Dugel,David Eichenbaum,Bora Eldem,Robert Engstrom,Joan Josep Escobar,Nicole Eter,David W. Faber,Naomi Falk,Leonard Feiner,Alvaro Fernandez Vega,Philip Ferrone,Marta Figueroa,Howard Fine,Mitchell Fineman,Gregory M. Fox,Catherine Francais,Pablo Franco,Samantha Fraser-Bell,Nicholas Fung,Federico Furno Sola,Richard Gale,Alfredo Garcia-Layana,Alfredo Garcia-Layana,Julie Gasperini,Maciej Gawecki,Faruque Ghanchi,Manjot Gill,Michel Giunta,David Glaser,Michaella Goldstein,Francisco Gomez Ulla,Fumi Gomi,Victor Gonzalez,Jordan Graff,Sunil Gupta,Rainer Guthoff,Robyn Guymer,Anton Haas,Robert Hampton,Katja Hatz,Ken Hayashi,Jeffrey Heier,Ewa Herba,Vrinda Hershberger,Patrick Higgins,Nancy Holekamp,Shigeru Honda,James Howard,Allen Hu,Stephen Huddleston,Tomohiro Iida,Hiroko Imaizumi,Yasuo Ito,Yasuki Ito,Sujit Itty,Golnaz Javey,Cameron Javid,Tatsushi Kaga,Jakub Kaluzny,Woong Kang,Kapil Kapoor,Levent Karabas,Tsutomu Kawasaki,Patrick Kelty,Agnes Kerenyi,Arshad Khanani,Ramin Khoramnia,Rahul Khurana,Kazuhiro Kimura,Kendra Klein-Mascia,Namie Kobayashi,Laurent Kodjikian,Hideki Koizumi,Gregg Kokame,Alexey Kulikov,Henry Kwong,Robert Kwun,Timothy Lai,Chi-Chun Lai,Laurent Lalonde,Paolo Lanzetta,Michael Larsen,Adrian Lavina,Won Ki Lee,ji Eun Lee,Seong Lee,Jaime Levy,Lucas Lindsell,Mimi Liu,Nikolas London,Andrew Lotery,David Lozano Rechy,Alan Luckie,David Maberley,Takatoshi Maeno,Sajjad Mahmood,Fuad Makkouk,Dennis Marcus,Alan Margherio,Helene Masse,Hisashi Matsubara,Raj Maturi,Sonia Mehta,Geeta Menon,Jale Mentes,Mark Michels,Yoshinori Mitamura,Paul Mitchell,Quresh Mohamed,Jordi Mones,Rodrigo Montemayor Lobo,Javier Montero,Jeffrey Moore,Ryusaburo Mori,Haia Morori-Katz,Raj Mukherjee,Toshinori Murata,Maria Muzyka-Wozniak,Marco Nardi,Niro Narendran,Massimo Nicolo,Jared Nielsen,Tetsuya Nishimura,Kousuke Noda,Anna Nowinska,Hideyasu Oh,Matthew Ohr,Annabelle Okada,Piotr Oleksy,Shinji Ono,Sengul Ozdek,Banu Ozturk,Luis Pablo,Kyu Hyung Park,D. Wilki Parke,Maria Cristina Parravano,Praveen Patel,Apurva Patel,Sunil Patel,Sugat Patel,Daniel Pauleikhoff,Ian Pearce,Joel Pearlman,Iva Petkova,Dante Pieramici,Nadezhda Pozdeyeva,Jawad Qureshi,Dorota Raczynska,Juan Ramirez Estudillo,Rajiv Rathod,Hessam Razavi,Carl Regillo,Gayatri Reilly,Federico Ricci,Ryan Rich,Bożena Romanowska-Dixon,Irit Rosenblatt,Jose Maria Ruiz Moreno,Stefan Sacu,Habiba Saedon,Usman Saeed,Min Sagong,Taiji Sakamoto,Sukhpal Sandhu,Laura Sararols,Mario Saravia,Ramin Schadlu,Patricio Schlottmann,Tetsuju Sekiryu,András Seres,Figen Sermet,Sumit Shah,Rohan Shah,Ankur Shah,Thomas Sheidow,Veeral Sheth,Chieko Shiragami,Bartosz Sikorski,Rufino Silva,Lawrence Singerman,Robert Sisk,Robert Sisk,Torben L. Sørensen,Eric Souied,David-J Spinak,Giovanni Staurenghi,Robert Steinmetz,Glenn Stoller,Robert Stoltz,Eric Suan,Ivan Suner,Yzer Suzanne,Ramin Tadayoni,Kanji Takahashi,Kei Takayama,Alexandre Taleb,James Talks,Hiroko Terasaki,John Thompson,Edit Toth-Molnar,Khoi Tran,Raman Tuli,Eduardo Uchiyama,Attila Vajas,Janneke Van Lith-Verhoeven,Balazs Varsanyi,Francesco Viola,Gianni Virgili,Gábor Vogt,Michael Völker,David Warrow,Pamela Weber,John A. Wells,Sanjeewa Wickremasinghe,Mark Wieland,Geoff Williams,Thomas Williams,David Wong,Wong,James Wong,Ian Wong,Robert Wong,Bogumil Wowra,Charles C. Wykoff,Ayana Yamashita,Kanako Yasuda,Gursel Yilmaz,Glenn Yiu,Ai Yoneda,Young Hee Yoon,Barak Yoreh,HyeongGon Yu,Seung Young Yu,Tatiana Yurieva,Alberto Zambrano,Barbara Zatorska,Carlos Zeolite,Rubens Belfort Jr,Se Woong Kang,King Wong
DOI: https://doi.org/10.1016/j.ophtha.2024.02.014
IF: 14.277
2024-02-01
Ophthalmology
Abstract:PURPOSE: To evaluate 2-year efficacy, durability, and safety of the bispecific antibody faricimab, which inhibits both angiopoietin-2 and VEGF-A.DESIGN: TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT03823300) were identically designed, randomized, double-masked, active comparator-controlled phase 3 noninferiority trials.PARTICIPANTS: Treatment-naive patients with neovascular age-related macular degeneration (nAMD) 50 years of age or older.METHODS: Patients were randomized (1:1) to intravitreal faricimab 6.0 mg up to every 16 weeks (Q16W) or aflibercept 2.0 mg every 8 weeks (Q8W). Faricimab fixed dosing based on protocol-defined disease activity at weeks 20 and 24 up to week 60, followed up to week 108 by a treat-and-extend personalized treatment interval regimen.MAIN OUTCOME MEASURES: Efficacy analyses included change in best-corrected visual acuity (BCVA) from baseline at 2 years (averaged over weeks 104, 108, and 112) and proportion of patients receiving Q16W, every 12 weeks (Q12W), and Q8W dosing at week 112 in the intention-to-treat population. Safety analyses included ocular adverse events (AEs) in the study eye through study end at week 112.RESULTS: Of 1326 patients treated across TENAYA/LUCERNE, 1113 (83.9%) completed treatment (n = 555 faricimab; n = 558 aflibercept). The BCVA change from baseline at 2 years was comparable between faricimab and aflibercept groups in TENAYA (adjusted mean change, +3.7 letters [95% confidence interval (CI), +2.1 to +5.4] and +3.3 letters [95% CI, +1.7 to +4.9], respectively; mean difference, +0.4 letters [95% CI, -1.9 to +2.8]) and LUCERNE (adjusted mean change, +5.0 letters [95% CI, +3.4 to +6.6] and +5.2 letters [95% CI, +3.6 to +6.8], respectively; mean difference, -0.2 letters [95% CI, -2.4 to +2.1]). At week 112 in TENAYA and LUCERNE, 59.0% and 66.9%, respectively, achieved Q16W faricimab dosing, increasing from year 1, and 74.1% and 81.2%, achieved Q12W or longer dosing. Ocular AEs in the study eye were comparable between faricimab and aflibercept groups in TENAYA (55.0% and 56.5% of patients, respectively) and LUCERNE (52.9% and 47.5% of patients, respectively) through week 112.CONCLUSIONS: Treat-and-extend faricimab treatment based on nAMD disease activity maintained vision gains through year 2, with most patients achieving extended dosing intervals.FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
ophthalmology